Novo Nordisk’s CagriSema Delivers Superior Diabetes Control
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
CHARLOTTESVILLE, Va., May 7, 2026 RIVANNA announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
CAMBRIDGE, Mass., May 6, 2026 Clear Scientific Inc., a clinical-stage biopharmaceutical company developing innovative therapies for acute drug intoxication,...
WINNIPEG, Manitoba, April 9, 2026 Emergent BioSolutions Inc. has announced a strategic partnership with the British Columbia Provincial Health...
SAN DIEGO, March 27, 2026 ARS Pharmaceuticals has received U.S. FDA approval to update the labeling of neffy® (epinephrine...
CHELMSFORD, Mass., Sept. 30, 2025 — The U.S. Food and Drug Administration (FDA) has approved the ZOLL Zenix Monitor/Defibrillator,...
